GlassScriptPhysician profile
Kenneth Daniel Ostmo
NPI 1578026647
$4,147.33
in general payments reported to CMS, 2019-2025
33 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $27.55 · 2022: $388 · 2023: $541 · 2024: $1,510 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,732.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,731.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $782.45 | 2024-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $476.22 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $379.16 | 2022-2025 | |
| Lilly USA, LLC | $279.65 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $274.93 | 2023-2025 | |
| Glaxosmithkline, LLC. | $244.76 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Teleflex LLC | $148.62 | 2025 | Urolift |
| Abbvie INC. | $141.46 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $138.79 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $135.13 | 2024-2025 | Veozah |
| Viiv Healthcare Company | $120.25 | 2022 | |
| Gilead Sciences, INC. | $108.01 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.29 | 2023-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $93.03 | 2023-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $82.80 | 2025 | Ibsrela |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $71.37 | 2023-2025 | Cologuard Collection Kit |
| Janssen Products, LP | $64.99 | 2022 | |
| Daiichi Sankyo INC. | $62.05 | 2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $55.55 | 2024-2025 | Voquezna |
| Eisai INC. | $51.15 | 2024 | |
| Abbott Laboratories | $50.26 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $38.90 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $35.07 | 2025 | Trintellix |
| Emd Serono, INC. | $32.13 | 2022-2023 | Serostim |
| Amgen INC. | $29.19 | 2024-2025 | Otezla, Repatha, Otezla |
| Jazz Pharmaceuticals INC. | $28.40 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $26.18 | 2022-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Inspire Medical Systems, INC. | $21.46 | 2023 | Inspire |
| Azurity Pharmaceuticals, INC. | $17.53 | 2025 | Alvesco |
| Otsuka America Pharmaceutical, INC. | $16.38 | 2024 | Rexulti |
| Theratechnologies INC. | $15.74 | 2021 | |
| Janssen Biotech, INC. | $14.54 | 2022 | |
| Vyera Pharmaceuticals, LLC | $13.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Ostmo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.